92 related articles for article (PubMed ID: 21544629)
21. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
Wada Y; Yoshida K; Suzuki T; Mizuiri H; Konishi K; Ukon K; Tanabe K; Sakata Y; Fukushima M
Int J Cancer; 2006 Aug; 119(4):783-91. PubMed ID: 16557585
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
Kakodkar NC; Peddinti RR; Tian Y; Guerrero LJ; Chlenski A; Yang Q; Salwen HR; Maitland ML; Cohn SL
Pediatr Blood Cancer; 2012 Oct; 59(4):642-7. PubMed ID: 22147414
[TBL] [Abstract][Full Text] [Related]
24. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Kawashima A; Takayama H; Arai Y; Tanigawa G; Nin M; Kajikawa J; Imazu T; Kinoshita T; Yasunaga Y; Inoue H; Nishimura K; Takada S; Nishimura K; Tsujimura A; Nonomura N;
Eur J Cancer; 2011 Jul; 47(10):1521-6. PubMed ID: 21550799
[TBL] [Abstract][Full Text] [Related]
25. Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
Ishii T; Marumo K
Int J Urol; 2004 Nov; 11(11):993-1000. PubMed ID: 15509204
[TBL] [Abstract][Full Text] [Related]
26. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
Takimoto CH; Awada A
Cancer Chemother Pharmacol; 2008 Apr; 61(4):535-48. PubMed ID: 18026728
[TBL] [Abstract][Full Text] [Related]
27. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
28. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
29. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
[TBL] [Abstract][Full Text] [Related]
31. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
32. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
[TBL] [Abstract][Full Text] [Related]
33. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Chang HR; Chen PN; Yang SF; Sun YS; Wu SW; Hung TW; Lian JD; Chu SC; Hsieh YS
Mol Carcinog; 2011 Oct; 50(10):811-23. PubMed ID: 21574189
[TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
[TBL] [Abstract][Full Text] [Related]
35. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
Li XF; Gong RY; Wang M; Yan ZL; Yuan B; Wang K; Shi LH
Biochem Biophys Res Commun; 2012 Feb; 418(3):531-6. PubMed ID: 22285185
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
[TBL] [Abstract][Full Text] [Related]
38. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
Kususda Y; Miyake H; Gleave ME; Fujisawa M
Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555
[TBL] [Abstract][Full Text] [Related]
39. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
[TBL] [Abstract][Full Text] [Related]
40. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
Zhang L; Bhasin M; Schor-Bardach R; Wang X; Collins MP; Panka D; Putheti P; Signoretti S; Alsop DC; Libermann T; Atkins MB; Mier JW; Goldberg SN; Bhatt RS
PLoS One; 2011 Apr; 6(4):e19144. PubMed ID: 21559452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
